Iquo Andrews-Cooper
Family · Aberdeen, MDNPI 1992182117
Payments from drug & device makers
Across 87 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$581
- AbbVie$418
- Otsuka America Pharmaceutical, Inc.$366
- Teva Pharmaceuticals USA, Inc.$315
- Neurocrine Biosciences, Inc.$124
- Axsome Therapeutics, Inc.$113
- plus $380 from 8 others
What the payments were for
- Food & beverage$2,296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 18 | $581 |
| AbbVie | 26 | $418 |
| Otsuka America Pharmaceutical, Inc. | 10 | $366 |
| Teva Pharmaceuticals USA, Inc. | 8 | $315 |
| Neurocrine Biosciences, Inc. | 5 | $124 |
| Axsome Therapeutics, Inc. | 3 | $113 |
| Vanda Pharmaceuticals Inc. | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 2 | $68 |
| Lundbeck LLC | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Johnson & Johnson | 1 | $24 |
| Corium, LLC | 1 | $18 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$426
- ARISTADA INITIO$107
- VIVITROL$100
- REXULTI$100
- Austedo XR$100
How this compares
$2,296 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $991 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $566 |
| Duloxetine Hcl | 15 | $320 |
| Buspirone Hcl | 38 | $249 |
| Hydroxyzine Hcl | 14 | $185 |
| Trazodone Hcl | 32 | $158 |
| Gabapentin | 13 | $119 |
| Benztropine Mesylate | 16 | $61 |
| Lamotrigine | 16 | $52 |
| Risperidone | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Other family in Aberdeen
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.